» Articles » PMID: 23807777

Reproducibility of Histological Cell Type in High-grade Endometrial Carcinoma

Overview
Journal Mod Pathol
Specialty Pathology
Date 2013 Jun 29
PMID 23807777
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Subclassification of endometrial carcinoma according to histological type shows variable interobserver agreement. The aim of this study was to assess specifically the interobserver agreement of histological type in high-grade endometrial carcinomas, recorded by gynecological pathologists from five academic centers across Canada. In a secondary aim, the agreement of consensus diagnosis with immunohistochemical marker combinations was assessed including six routine (TP53, CDKN2A (p16), ER, PGR, Ki67, and VIM) and six experimental immunohistochemical markers (PTEN, ARID1A, CTNNB1, IGF2BP3, HNF1B, and TFF3). The paired interobserver agreement ranged from κ 0.50 to 0.63 (median 0.58) and the intraobserver agreement from κ 0.49 to 0.67 (median 0.61). Consensus about histological type based on morphological assessment was reached in 72% of high-grade endometrial carcinomas. A seven-marker immunohistochemical panel differentiated FIGO grade 3 endometrioid from serous carcinoma with a 100% concordance rate compared with the consensus diagnosis. More practically, a three-marker panel including TP53, ER, and CDKN2A (p16) can aid in the differential diagnosis of FIGO grade 3 endometrioid from endometrial serous carcinoma. Our study demonstrates that the inter- and intraobserver reproducibility of histological type based on morphology alone are mostly moderate. Ancillary techniques such as immunohistochemical marker panels are likely needed to improve diagnostic reproducibility of histological types within high-grade endometrial carcinomas.

Citing Articles

Translational Gynecologic Oncology at Midlife and Beyond: A Difficult Bedside to Community Transition.

Patni R J Midlife Health. 2025; 15(4):225-227.

PMID: 39959726 PMC: 11824929. DOI: 10.4103/jmh.jmh_193_24.


External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center.

Tsolakidis D, Zouzoulas D, Sofianou I, Karalis T, Chatzistamatiou K, Theodoulidis V Medicina (Kaunas). 2024; 60(9).

PMID: 39336462 PMC: 11434438. DOI: 10.3390/medicina60091421.


Impact of Robotic Assistance on Minimally Invasive Surgery for Type II Endometrial Cancer: A National Cancer Database Analysis.

Lamiman K, Silver M, Goncalves N, Kim M, Alagkiozidis I Cancers (Basel). 2024; 16(14).

PMID: 39061223 PMC: 11274470. DOI: 10.3390/cancers16142584.


The association between body mass index and molecular subtypes in endometrial carcinoma.

Smith D, Kang E, Nelson G, Lee C, Kobel M, Aubrey C Gynecol Oncol Rep. 2024; 54:101447.

PMID: 39055290 PMC: 11269851. DOI: 10.1016/j.gore.2024.101447.


Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications.

Kuhn E, Gambini D, Runza L, Ferrero S, Scarfone G, Bulfamante G Cancers (Basel). 2024; 16(13).

PMID: 39001520 PMC: 11240465. DOI: 10.3390/cancers16132458.